ライフサイエンスコーパス: reverse transcriptase

1 hepatitis C virus (HCV) polymerase and HIV-1 reverse transcriptase.

2 elop HIVAN in the absence of HIV protease or reverse transcriptase.

3 in the RNA-binding domain of the telomerase reverse transcriptase.

4 , and is antagonized by inhibitors of the L1 reverse transcriptase.

5 matches using a thermostable group II intron reverse transcriptase.

6 le nucleotide incorporation catalyzed by HIV reverse transcriptase.

7 templating RNA is the core of the telomerase reverse transcriptase.

8 of Moloney murine leukemia virus (MMLV)-type reverse transcriptases.

9 activity catalyzed by wild-type and variant reverse transcriptases.

10 d by human DNA polymerases relative to viral reverse transcriptases.

11 tures of a predicted DGR system, including a reverse transcriptase, a template repeat and one (or mor

12 emonstrate this by combined inhibition of L1 reverse transcriptase activity and the Chk2-dependent DN

13 Licensed antivirals target the HBV reverse transcriptase activity but fail to eliminate ccc

14 able viral family A polymerase with inherent reverse transcriptase activity for use in RT-PCR.

15 the flap RNA strand of an RNA:DNA hybrid and reverse transcriptase activity on a DNA-primed RNA templ

16 ation and pharmacologically inhibiting viral reverse transcriptase activity prevents degenerative phe

17 osphorylated Tbk1 and, importantly, blocking reverse transcriptase activity suppressed the expression

18 ology and Mn(2+)-dependent virion-associated reverse transcriptase activity typical of a gammaretrovi

19 in high thermostability and display elevated reverse transcriptase activity.

20 The effect of mutations on virus reverse-transcriptase activity and infectiousness was an

21 validate the platform, we evolved the HIV-1 reverse transcriptase against N(1)-methyladenosine (m(1)

22 -DNA-dependent DNA polymerase activity among reverse transcriptases, an observation consistent with s

23 nsduced with genes encoding human telomerase reverse transcriptase and doxycycline-inducible MyoD, ge

24 ted next-generation sequencing assay for the reverse transcriptase and gp41 genes.

25 y inhibited HIV in combination with clinical reverse transcriptase and integrase inhibitors.

26 ed on a reversibly linked combination of HIV reverse transcriptase and protease inhibitors.

27 Mutations in the telomerase reverse transcriptase and telomerase RNA component genes

28 e N-terminally biotinylated human telomerase reverse transcriptase and using a newly developed method

29 A and RNA targets using polymerase with both reverse-transcriptase and strand displacement activities

30 or all three drug-target proteins: protease, reverse transcriptase, and integrase; a comparative anal

31 ts remains challenging as retroviral-derived reverse transcriptases are often not sufficiently thermo

32 on stalls, consistent with blockage of viral reverse transcriptase at gRNA branch points.

33 es, which may signal intrinsic difference of reverse transcriptase between these viral species or dif

34 published crystal structures showed that HIV reverse transcriptase binds only two metal ions prior to

35 tures and G-rich sequences, ahead of diverse reverse transcriptases can be strong stimulators for sli

36 kly silenced, specifically due to telomerase reverse transcriptase component (TERT) down-regulation,

37 able effectors, which vary either by using a reverse transcriptase-dependent diversity-generating sys

38 The optimal evolved reverse transcriptase enabled detection of well-characte

39 genes have also been created in primates by reverse transcriptase-encoding elements like LINE-1 or e

40 is comprised of an RNA component, TLC1, the reverse transcriptase, Est2, and regulatory subunits, in

41 This work develops and validates the reverse transcriptase evolution platform, and provides n

42 and IN, as well as the spatial separation of reverse transcriptase from the viral genome during early

43 itors, which are CRISPR-Cas9 nickase (H840A)-reverse transcriptase fusions programmed with prime edit

44 Since 2006, HIV protease and reverse transcriptase gene (pol) sequences from drug res

45 e determined by analyzing 155,462 single HIV reverse transcriptase gene (RT) and 6,985 vif sequences

46 ntegrations, such as those in the telomerase reverse transcriptase gene (TERT) promoter, activate gen

47 s here show that at the same shift motif HIV reverse transcriptase generates -1 and +1 indels with th

48 We obtained 58 protease/reverse transcriptase genotypes.

49 of functional TNA aptamers that bind to HIV reverse transcriptase (HIV RT) with K(D)'s of ~0.4-4.0 n

50 on assays using human immunodeficiency virus reverse transcriptase (HIV-RT) and three DNA-polymerases

51 by the telomerase complex that contains the reverse transcriptase hTERT and RNA template TERC/hTR.

52 riptional activation of the human telomerase reverse transcriptase (hTERT) gene, which remains repres

53 uencing and techniques based on quantitative reverse transcriptase in real time, we evaluated 60 mela

54 tic ribonucleoprotein complex that acts as a reverse transcriptase in the elongation of telomeres.

55 We also show that hpol eta acts as a reverse transcriptase in the presence of damaged ribonuc

56 d through POT1/TRF2 and via human telomerase reverse transcriptase inhibition through JNK activation.

57 ivity, particle incorporation, inhibition of reverse transcriptase inhibition, and DNA cytidine deami

58 iation (0.71 [0.61-0.82]) and non-nucleoside reverse transcriptase inhibitor (0.68 [0.51-0.90]) or in

59 luated for drug resistance to non-nucleoside reverse transcriptase inhibitor (NNRTI) at codons Lys103

60 antiretroviral therapy with a non-nucleoside reverse transcriptase inhibitor (NNRTI) plus two NRTIs h

61 eficiency virus type 1 (HIV-1) nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance mutat

62 e risk factors associated with nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance.

63 leoside human immunodeficiency virus (HIV)-1 reverse transcriptase inhibitor (NNRTI), was safe and ef

64 protease inhibitor (PI)-, and nonnucleoside reverse transcriptase inhibitor (NNRTI)-based ART betwee

65 irus type 1 (HIV-1) by a novel nonnucleoside reverse transcriptase inhibitor (NNRTI).

66 ne/efavirenz, presence of both nonnucleoside reverse transcriptase inhibitor (NNRTI)/nucleoside rever

67 dine or emtricitabine) plus a non-nucleoside reverse transcriptase inhibitor (NNRTI; nevirapine or ef

68 SPNs) of the highly water-soluble nucleoside reverse transcriptase inhibitor (NRTI) emtricitabine (FT

69 apy (ART) for HIV patients is the nucleoside reverse transcriptase inhibitor (NRTI) is tenofovir.

70 he clinically administered nucleoside analog reverse transcriptase inhibitor azidothymidine (AZT).

71 Remarkably, reverse transcriptase inhibitor AZT-treated Chk2 mutant

72 localization of LysRS, but treatment with a reverse transcriptase inhibitor does not, suggesting tha

73 For nucleotide reverse transcriptase inhibitor DRMs, sensitivity and sp

74 For non-nucleotide reverse transcriptase inhibitor DRMs, sensitivity and sp

75 tance to older thymidine analogue nucleoside reverse transcriptase inhibitor drugs has been identifie

76 Treatment of aged mice with the nucleoside reverse transcriptase inhibitor lamivudine downregulated

77 e transcriptase inhibitor (NNRTI)/nucleoside reverse transcriptase inhibitor PDR vs no PDR was associ

78 0 copies/mL, and 79% were on a nonnucleoside reverse transcriptase inhibitor regimen.

79 e (63%) of eight had archived non-nucleoside reverse transcriptase inhibitor resistance-associated mu

80 long-acting formulation of the nonnucleoside reverse transcriptase inhibitor rilpivirine (RPV LA) has

81 nhibitor (PI) lopinavir (LPV) and nucleoside reverse transcriptase inhibitor tenofovir alafenamide (T

82 erapy (ART) containing the modern nucleoside reverse transcriptase inhibitor tenofovir.

83 Doravirine is a novel, non-nucleoside reverse transcriptase inhibitor that has shown non-infer

84 RNA concentration and background nucleoside reverse transcriptase inhibitor therapy, to doravirine (

85 only individuals on first-line nonnucleoside reverse transcriptase inhibitor-based ART regimens.

86 ofile, which support its use as a nucleoside reverse transcriptase inhibitor-sparing and protease inh

87 on a first-generation nonnucleoside analogue reverse transcriptase inhibitor.

88 criptase inhibitor (NRTI) plus nonnucleoside reverse-transcriptase inhibitor (43%), NRTI plus integra

89 Doravirine (DOR), a novel non-nucleoside reverse-transcriptase inhibitor (NNRTI), is active again

90 ling therapy on a TDF/XTC plus nonnucleoside reverse-transcriptase inhibitor (NNRTI)-containing regim

91 mmon ART regimens were nucleoside/nucleotide reverse-transcriptase inhibitor (NRTI) plus nonnucleosid

92 RNA from HIV-1-infected cells treated with a reverse-transcriptase inhibitor or with heat-inactivated

93 ommon 3DR was dolutegravir plus 2 nucleoside reverse transcriptase inhibitors (46.9%).

94 ART regimens based on either Non-Nucleoside Reverse Transcriptase Inhibitors (EFV) or ritonavir-boos

95 (darunavir, atazanavir), and 2 nonnucleoside reverse transcriptase inhibitors (nevirapine, efavirenz)

96 ountries are moving away from non-nucleoside reverse transcriptase inhibitors (NNRTI) and transitioni

97 n than protease inhibitors or non-nucleoside reverse transcriptase inhibitors (NNRTI), with dolutegra

98 40%), boosted ARVs (30%), and non-nucleoside reverse transcriptase inhibitors (NNRTIs) (32%) based re

99 e prevalence of resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) reached 45% (9

100 Rising resistance of HIV-1 to non-nucleoside reverse transcriptase inhibitors (NNRTIs) threatens the

101 nd tallied major mutations to non-nucleoside reverse transcriptase inhibitors (NNRTIs), nucleoside re

102 itted drug resistance (TDR) to nonnucleoside reverse transcriptase inhibitors (NNRTIs), nucleoside re

103 an were protease inhibitors or nonnucleoside reverse transcriptase inhibitors (NNRTIs), with dolutegr

104 Prior exposure to both nucleoside reverse transcriptase inhibitors (NRTIs) and non-NRTIs a

105 Nucleoside reverse transcriptase inhibitors (NRTIs) are widely used

106 of the OPTIONS trial showed that nucleoside reverse transcriptase inhibitors (NRTIs) can be safely o

107 navir-boosted lopinavir, plus two nucleoside reverse transcriptase inhibitors (NRTIs) in adults in wh

108 Nucleoside reverse transcriptase inhibitors (NRTIs) were the first

109 Nucleoside reverse transcriptase inhibitors (NRTIs) with L-stereoch

110 ranscriptase inhibitors (NNRTIs), nucleoside reverse transcriptase inhibitors (NRTIs), and protease i

111 ranscriptase inhibitors (NNRTIs), nucleoside reverse transcriptase inhibitors (NRTIs), and protease i

112 ested to be a major substrate for TREX1, and reverse transcriptase inhibitors (RTIs) were proposed as

113 and cohorts B (B1, best available nucleoside reverse transcriptase inhibitors [NRTIs] plus ritonavir-

114 ce; 1 EFV, emergent resistance to nucleoside reverse transcriptase inhibitors and nonnucleoside rever

115 ntification of thymidine analogue nucleoside reverse transcriptase inhibitors as the cause of lipoatr

116 dence that telomerase can add the nucleotide reverse transcriptase inhibitors ddITP and AZT-TP to the

117 rhesus macaques with protease, integrase, or reverse transcriptase inhibitors for 1 to 2 or for 5 to

118 virenz (EFV; 600 mg daily) with 2 nucleoside reverse transcriptase inhibitors for 52 weeks.

119 infants received ineffective non-nucleoside reverse transcriptase inhibitors for PMTCT.

120 The antiviral activity of nucleoside reverse transcriptase inhibitors is often hampered by in

121 resistance to the co-administered nucleoside reverse transcriptase inhibitors might reduce effectiven

122 ical responses to cART based on 2 nucleoside reverse transcriptase inhibitors plus 1 ritonavir-booste

123 The regimen consisted of two nucleoside reverse transcriptase inhibitors plus nevirapine dosed a

124 e transcriptase inhibitors and nonnucleoside reverse transcriptase inhibitors).

125 Among nucleoside/nucleotide reverse transcriptase inhibitors, tenofovir alafenamide

126 without evidence of resistance to nucleoside reverse transcriptase inhibitors.

127 ict PrEP potency for all drug classes except reverse transcriptase inhibitors.

128 rs (PI) with the same backbone of Nucleoside Reverse Transcriptase Inhibitors.

129 4-5.9]); all mutations were to nonnucleoside reverse transcriptase inhibitors.

130 , both with investigator-selected nucleoside reverse transcriptase inhibitors: emtricitabine and teno

131 Nucleoside reverse-transcriptase inhibitors (NRTI), drugs approved

132 ndard protease inhibitor plus two nucleoside reverse-transcriptase inhibitors (NRTIs) second-line com

133 Nine nucleoside reverse-transcriptase inhibitors and 37 nucleoside/heter

134 Structural studies of reverse transcriptase initiation complexes (RTICs) have

135 ts suggest that hpol eta is one of the major reverse transcriptases involved in physiological process

136 on that is a hallmark of ageing, and that L1 reverse transcriptase is a relevant target for the treat

137 Lentiviral replication mediated by reverse transcriptase is considered to be highly error p

138 ain in RB69 DNA polymerase (Arg-482) and HIV reverse transcriptase (Lys-65) were previously observed

139 the three introns, and intron loss is likely reverse transcriptase mediated.

140 s that large A3G oligomers could block HIV-1 reverse transcriptase-mediated DNA synthesis, thereby in

141 Here, we uncovered that telomerase reverse transcriptase null (Tert(-/-)) mESCs exhibit gen

142 rupt the binding between the protein subunit reverse transcriptase of the telomerase and its nucleic

143 , a bacterium that lacks either a standalone reverse transcriptase or its fusion to spacer integrase

144 atitis B virus (HBV) encodes a multifunction reverse transcriptase or polymerase (P), which is compos

145 CRISPR/Cas9 knockout of human telomerase reverse transcriptase or treatment with the telomerase-m

146 p160, gp41), gag (capsid, p24; matrix, p17), reverse transcriptase (p66/51), and integrase (p31) were

147 Using an MDV genome quantitative reverse transcriptase PCR (qRT-PCR) array and chromatin

148 asa, DRC, were EBOV positive by quantitative reverse transcriptase PCR (qRT-PCR).

149 cular assays, such as conventional real-time reverse transcriptase PCR (rRT-PCR), detect total RNA in

150 20 to 40 copies/ml) but can be quantified by reverse transcriptase PCR (RT-PCR) assays with single-co

151 post-symptom onset or post-initial positive reverse transcriptase PCR (RT-PCR) result were 92.9% (78

152 the control) and a prototype, and SARS-CoV-2 reverse transcriptase PCR (RT-PCR) results were compared

153 A real-time reverse transcriptase PCR (RT-PCR) screening revealed th

154 atory-developed test (modified CDC 2019-nCoV reverse transcriptase PCR [RT-PCR] assay with RNA extrac

155 A real-time quantitative reverse transcriptase PCR assay with single-copy sensiti

156 This was confirmed by quantitative reverse transcriptase PCR in infected and uninfected gas

157 acteriology, immunoassays, gel-based PCR and reverse transcriptase PCR, and quantitative real-time PC

158 mRNA levels from tissues are measured using reverse transcriptase PCR, microarray analysis or high-t

159 RL), (ii) detection of T. pallidum in CSF by reverse transcriptase PCR, or (iii) new vision loss or h

160 ected by polymerase chain reaction (PCR) and reverse transcriptase PCR.

161 ed using polymerase chain reaction (PCR) and reverse transcriptase PCR.

162 Quantitative reverse-transcriptase PCR (qRT-PCR) analysis showed that

163 al models using flow cytometry, quantitative reverse-transcriptase PCR (qRT-PCR), and RNA-Seq for PD-

164 d gene-expression changes using quantitative reverse-transcriptase PCR (qRT-PCR), immunofluorescence,

165 mRNA sequencing, and quantitative real-time reverse transcriptase-PCR of tissue biopsy samples.

166 were evaluated with microarray profiling and reverse transcriptase-PCR.

167 were determined using real-time quantitative reverse transcriptase-PCR.

168 an expanded redesign of the WHO-recommended reverse transcriptase PCRs (RT-PCRs).

169 rst year of life were tested by quantitative reverse transcriptase polymerase chain reaction (PCR) an

170 syndrome coronavirus 2 (SARS-CoV-2) based on reverse transcriptase polymerase chain reaction (RT-PCR)

171 ating SARS-CoV-2 culture with the results of reverse transcriptase polymerase chain reaction (RT-PCR)

172 ient with perforated peptic ulcer, real time reverse transcriptase polymerase chain reaction (RT-PCR)

173 pment; however, they are less sensitive than reverse transcriptase polymerase chain reaction (RT-PCR)

174 the expression pattern of several genes via reverse transcriptase polymerase chain reaction (RT-PCR)

175 2019 (COVID-19), a SARS-CoV-2 virus-specific reverse transcriptase polymerase chain reaction (RT-PCR)

176 n area with history of a positive SARS-CoV-2 reverse transcriptase polymerase chain reaction (RT-PCR)

177 Quantitative reverse transcriptase polymerase chain reaction and West

178 vity of BCR-ABL transcript in a quantitative reverse transcriptase polymerase chain reaction assay co

179 ve nasopharyngeal or lower respiratory tract reverse transcriptase polymerase chain reaction assays,

180 In April 2020, all but 5 patients (96%) had reverse transcriptase polymerase chain reaction based CO

181 during the CABG surgery and were analyzed by reverse transcriptase polymerase chain reaction for peri

182 tation affecting splicing as demonstrated by reverse transcriptase polymerase chain reaction performe

183 Both reverse transcriptase polymerase chain reaction tests an

184 020, with COVID-19 confirmation on real-time reverse transcriptase polymerase chain reaction were ide

185 estern blot) and messenger RNA (quantitative reverse transcriptase polymerase chain reaction, RNAscop

186 Real-time reverse transcriptase polymerase chain reaction-based as

187 re included in our study (n=38 patients with reverse transcriptase polymerase chain reaction-confirme

188 redictive values of chest CT versus those of reverse transcriptase polymerase chain reaction.

189 ction and mRNA expression using quantitative reverse transcriptase polymerase chain reaction.

190 testing for SARS-CoV-2, including real-time reverse-transcriptase polymerase chain reaction (rRT-PCR

191 atory specimens were tested for influenza by reverse-transcriptase polymerase chain reaction (RT-PCR)

192 syndrome coronavirus 2 (SARS-CoV-2) based on reverse-transcriptase polymerase chain reaction (RT-PCR)

193 Quantitative reverse-transcriptase polymerase chain reaction analysis

194 cimens were tested for influenza by means of reverse-transcriptase polymerase chain reaction and were

195 This study characterizes the prevalence of reverse-transcriptase polymerase chain reaction results

196 nts was carried out by immunohistochemistry, reverse-transcriptase polymerase chain reaction, and gen

197 ically confirmed dengue by serotype-specific reverse-transcriptase polymerase chain reaction.

198 patients had subsequent proof of COVID-19 by reverse-transcriptase polymerase chain reaction.

199 Using data from 170 reverse transcriptase-polymerase chain reaction (RT-PCR)

200 SARS-CoV-2 infection confirmed by real-time reverse transcriptase-polymerase chain reaction (RT-PCR)

201 can be combined with quantitative real-time reverse transcriptase-polymerase chain reaction (RT-qPCR

202 sm were analyzed by multiplexed quantitative reverse transcriptase-polymerase chain reaction after th

203 Specific real-time reverse transcriptase-polymerase chain reaction targetin

204 et SFRP1 was also quantified by quantitative reverse transcriptase-polymerase chain reaction, and DNA

205 Quantitative reverse transcriptase-polymerase chain reaction, Western

206 re tested for RSV infections using real-time reverse transcriptase-polymerase chain reaction.

207 ors and insulin resistance were evaluated by reverse transcriptase-polymerase chain reaction.

208 ND1 and D-loop were measured by quantitative reverse transcriptase-polymerase chain reaction.

209 ed in a subgroup of these women on real-time reverse-transcriptase-polymerase-chain-reaction (rRT-PCR

210 f which 2485 (4%) were confirmed by means of reverse-transcriptase-polymerase-chain-reaction (RT-PCR)

211 had a positive result for Ebola virus RNA on reverse-transcriptase-polymerase-chain-reaction assay we

212 inflammatory programs that were dependent on reverse transcriptase produced from LINE1s.

213 red Cas9 endonuclease fused to an engineered reverse transcriptase, programmed with a prime editing g

214 hree enzymes required for virus replication: reverse transcriptase, protease, and integrase.

215 or V-Plex, and mRNA levels were assessed via reverse transcriptase quantitative PCR (qRT-PCR).

216 Reverse transcriptase quantitative PCR (RT-qPCR) confirm

217 enger RNA (tmRNA), pre-16S rRNA, and rpoB by reverse transcriptase quantitative PCR (RT-qPCR) showed

218 IAV isolate confirmed by immunofluorescence, reverse transcriptase quantitative PCR (RT-qPCR), and NG

219 Comparison of virus titration results to reverse transcriptase quantitative PCR and measurement o

220 stresses were assessed using microarray and reverse transcriptase quantitative PCR.

221 and protein translation were confirmed using reverse transcriptase quantitative polymerase chain reac

222 ing, publicly available expression data, and reverse transcriptase quantitative polymerase chain reac

223 Cytokine expression was examined by reverse-transcriptase quantitative PCR, intracellular fl

224 NA profiling using high throughput stem-loop reverse-transcriptase quantitative polymerase chain reac

225 0 samples were confirmed positive for YFV by reverse transcriptase-quantitative polymerase chain reac

226 Reverse-transcriptase-quantitative PCR (RT-Q-PCR) and RT

227 ha, IL-17, RANKL, and OPG) was determined by reverse transcriptase - real-time polymerase chain react

228 enced HIV-1 env (C2-V3), gag (p24), and pol (reverse transcriptase) regions amplified from cell-free

229 hat defines TERT and separates it from other reverse transcriptases remains a subject of debate.

230 Telomerase is the essential reverse transcriptase required for linear chromosome mai

231 Using Chlamydomonas and human telomerase reverse transcriptase-retinal pigment epithelial cell li

232 bound to the Tribolium castaneum telomerase reverse transcriptase reveals an atypical interaction, i

233 nucleotide analogs capable of inhibiting the reverse transcriptase (RT) activity of HIV and hepatitis

234 , but brain SGR uses an RNA intermediate and reverse transcriptase (RT) activity, which are character

235 zymes competitively bind the RNA template or reverse transcriptase (RT) and act as a roadblock to DNA

236 Human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) and protease sequences were o

237 e conjugates act as dNTP analogues and HIV-1 reverse transcriptase (RT) catalytically incorporates th

238 HIV type I (HIV-1) reverse transcriptase (RT) catalyzes the conversion of v

239 Reverse transcriptase (RT) enzymes are indispensable too

240 RNA aptamers that bind HIV-1 reverse transcriptase (RT) inhibit RT in enzymatic and v

241 mice remained naive or were treated with the reverse transcriptase (RT) inhibitor lamivudine (3TC).

242 hway, human CD4(+) T cells failed to mount a reverse transcriptase (RT) inhibitor-sensitive immune re

243 Nucleoside analogue reverse transcriptase (RT) inhibitors, such as entecavir

244 HIV-1 reverse transcriptase (RT) is an essential enzyme, targe

245 tions, G112D and M230I, were selected in the reverse transcriptase (RT) of human immunodeficiency vir

246 HIV-1 reverse transcriptase (RT) possesses both DNA polymerase

247 long the viral RNA genomic template in which reverse transcriptase (RT) stalls.

248 template-switching oligo (TSO), allowing the reverse transcriptase (RT) to switch templates and conti

249 Deep sequencing of HIV reverse transcriptase (RT) was performed (Roche/454), an

250 tified through a virtual screening using HIV-reverse transcriptase (RT), adenylate/guanylate kinase,

251 enced and subtyped in the gag, protease (PR)-reverse transcriptase (RT), integrase (IN) and/or envelo

252 Human immunodeficiency virus (HIV) reverse transcriptase (RT)-associated ribonuclease H (RN

253 patients: the New York SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Panel (modifie

254 sts: a modified version of the CDC Real-time Reverse Transcriptase (RT)-PCR Diagnostic Panel and two

255 detected in respiratory samples by Real-time Reverse Transcriptase (RT)-PCR or other molecular method

256 host nucleus, we opted for developing HIV-1 reverse transcriptase (RT)-specific 2'-deoxynucleoside a

257 that RHA enhances the processivity of HIV-1 reverse transcriptase (RT).

258 geting the essential viral polymerase, HIV-1 reverse transcriptase (RT).

259 arily driven by an increase in nonnucleoside reverse-transcriptase (RT) inhibitor (NNRTI) resistance

260 g and cDNA library steps are replaced with a reverse-transcriptase (RT) reaction that adds a unique m

261 The reverse transcriptases (RTs) encoded by mobile group II

262 Bacterial group II intron reverse transcriptases (RTs) function in both intron mob

263 The ability of reverse transcriptases (RTs) to synthesize a complementa

264 We report here crystal structures of a reverse transcriptase RTX, which was evolved in vitro fr

265 Here, we used thermostable group II intron reverse transcriptase sequencing (TGIRT-seq) combined wi

266 is composed of a dedicated RNA subunit and a reverse transcriptase (telomerase reverse transcriptase

267 ost frequently mutated genes were telomerase reverse transcriptase (TERT) (58.1%), catenin beta 1 (CT

268 rase contains a catalytic core of telomerase reverse transcriptase (TERT) and telomerase RNA (TER).

269 Mutations in the genes encoding telomerase reverse transcriptase (TERT) and telomerase's RNA compon

270 alytic core of which includes the telomerase reverse transcriptase (TERT) and the non-coding human te

271 nonamplified neuroblastomas with telomerase reverse transcriptase (TERT) gene overexpression and coo

272 we extend these observations into telomerase reverse transcriptase (TERT) immortalized oral keratinoc

273 uisition of promoter mutations in telomerase reverse transcriptase (TERT) in blood leukocytes of appr

274 Because telomerase reverse transcriptase (TERT) is usually the limiting com

275 Similarly, telomerase reverse transcriptase (tert) mutant zebrafish have prema

276 structures of Tribolium castaneum telomerase reverse transcriptase (TERT) throughout its catalytic cy

277 ns in the same genes, such as the telomerase reverse transcriptase (TERT), but through differential e

278 of telomere length-1 (RTEL1) and telomerase reverse transcriptase (TERT), genes involved in telomere

279 mong 6,835 cancers, 73% expressed telomerase reverse transcriptase (TERT), which was associated with

280 e transcriptional upregulation of telomerase reverse transcriptase (TERT).

281 integral telomerase RNA (TER) and telomerase reverse transcriptase (TERT).

282 more, an evident up-regulation of telomerase reverse-transcriptase (TERT) expression was detected in

283 unit and a reverse transcriptase (telomerase reverse transcriptase [TERT]).

284 Thermostable group II intron reverse transcriptases (TGIRTs) with high fidelity and p

285 Telomerase is a specialized reverse transcriptase that adds GGTTAG repeats to chromo

286 Telomerase, a unique reverse transcriptase that specifically extends the ends

287 directed evolution that rapidly selects for reverse transcriptases that install mutations at sites o

288 While some Type III systems encode a reverse transcriptase to acquire spacers from foreign tr

289 is a DNA virus that utilizes a virus-encoded reverse transcriptase to convert an RNA intermediate, te

290 rkable genetic elements that use error-prone reverse transcriptases to generate vast sequence variant

291 roelements, retrons, that employ specialized reverse transcriptases to produce noncoding intracellula

292 While c-TDR requires reverse transcriptase, translesion DNA polymerase zeta (

293 n as ISL and MK-8591) is a unique nucleoside reverse transcriptase translocation inhibitor in clinica

294 -fluoro-2'-deoxyadenosine [EFdA]) is a novel reverse transcriptase-translocation inhibitor.

295 tiviruses encoding HIV (lacking protease and reverse transcriptase), Vpr, or vector control.

296 dramatically augmented Thumb domain, and of reverse transcriptase, which extends its Thumb with the

297 Iterative rounds of selection yielded reverse transcriptases with both robust read-through and

298 In the presence of other reverse transcriptases with higher fidelity like AMV-RT,

299 , we tested a combination of four commercial reverse transcriptases with two priming techniques to fa

300 ) extracts, and they were substrates for HIV-reverse transcriptase without being substrates for DNA-p